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ABSTRACT
Background Initiating and adjusting insulin treat-
ment for people with type 2 diabetes (T2D) requires
frequent clinician contacts both face-to-face and
by telephone. We explored the use of a telehealth
system to oﬀer additional support to these patients.
Methods Twenty-three patients with uncontrolled
T2D were recruited from nine general practices to
assess the feasibility and acceptability of telehealth
monitoring and support for insulin initiation and
adjustment. The intervention included a standard
algorithm for self-titration of insulin dose, a
Bluetooth enabled glucose meter linked to a mobile
phone, an integrated diary to record insulin dose,
feedback of charted blood glucose data and tele-
health nurse reviewwith telephone follow-up. Add-
itional contact with patients was initiated when no
readings were transmitted for >3 days or when
persistent hyper- or hypoglycaemia was identiﬁed.
Reponses of patients and clinicians to the system
were assessed informally.
Results The mean (SD) patient age was 58 years
(12) with 78% male. The mean (SD) diabetes dur-
ation was 6.4 years (4.5), HbA1c at baseline was
9.5% (2.2), and the decrease in HbA1c at three
months was 0.52% (0.91) with an insulin dose
increase of 9 units (26). A mean (SD) of 160 (93)
blood glucose readings was transmitted per patient
in these three months. Practice nurses and general
practitioners (GPs) viewed the technology as having
the potential to improve patient care. Most patients
were able to use the equipment with training and
welcomed review of their blood glucose readings by
a telehealth nurse.
Conclusions Although the concept of telehealth
monitoring is unfamiliar to most patients and prac-
tice nurses, the technology improved the support
available for T2D patients commencing insulin
treatment.
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Introduction
Supporting people in self-management of their long-
term conditions is a key healthcare objective.1 Evidence
for the beneﬁt of programmes to fulﬁl this require-
ment is strong,2 but there is a need to extend current
interventions to provide support for the increasing
number of patients in ways that are better integrated
with their day-to-day lives. Appropriate use of tech-
nology canmake amajor contribution towards enabling
patients to monitor their health and make informed
decisions about treatment. The term ‘telehealth’ is used
to denote the use of a technology capable of providing
the elements required for remote exchange of physio-
logical data by electronic means, enabling self-manage-
ment. Patients can use this technology at convenient
times of day, at relevant stages in the progression of
their condition, and with integration of clinician
support. This type of technology has potential for
wide reach at an aﬀordable cost.
Self management has potential to play a major role
in improving outcomes for people with diabetes. Treat-
ments of proven eﬃcacy are available,3–5 yet these
treatments are not always used appropriately. Insulin
treatment for patients with T2D can bring about reduc-
tions in glycaemia,6 but patients may be reluctant to
start using or to increase their insulin dose. Studies
have suggested lack of acceptance of insulin therapy
relates to anxiety about pain of injection, concerns
that the disease has progressed, association of insulin
therapy with catastrophic events, fear of hypoglycaemia,
social embarrassment, perceived restrictions in lifestyle,
and concern about weight gain.7,8 Support and re-
assurance are therefore needed to help acceptance of
treatment, but the scale of the problem demands inno-
vative approaches. Current clinical pathways for sup-
porting patients involve either frequent clinic visits or
routine visits supplemented by frequent telephone calls.
Both options involve exchanging information about
blood glucose results and providing advice on adjust-
ing treatment, but they are also very time consuming.
Support using telehealth technology may be a poten-
tial solution to this problem.
Telehealth is a term encompassing healthcare prac-
tices, particularly those beneﬁting patients with long-
term conditions, which are supported by innovative
telecommunication strategies.9 Our current telehealth
project was preceded by a trial using a telehealth system
to support patients with type 1 diabetes.10 Building on
knowledge already gained we extended this work to
examine the system’s potential to support patients with
T2D to adjust their insulin dose to improve glycaemic
control. We report here the way in which the tele-
health system was set up and used, and the initial
experiences and level of engagement of clinicians and
patients.
Methods
We undertook an informal review of the experience of
patients and clinicians participating in a cohort study
to evaluate the impact of telehealth support for people
with T2D treated with insulin. Data for this review
were obtained from notesmade at the time of contacts
with patients, clinicians and practice teams, informal
observations by members of the telehealth nurse and
research team, and from comments made by patients
in completing study questionnaires.
The study was set in larger (list size >6500)
Oxfordshire general practices. Patients with HbA1c
>7.5% commencing treatment with a basal insulin
regimen during the past 12 months were invited to
take part. Patients unable to use a mobile phone for
visual or sensory reasons or who were unable to self-
test their blood glucose were excluded from the study.
All patients and practices provided material for this
review.
Patients entering the study were given a mobile
phone with a preloaded software application, and a
blood glucose meter linked to the phone via a
BluetoothTM cradle. The telehealth software used in
the study was based on a commercially available system
t+ Diabetes (supplied by t+ Medical, Abingdon, UK).
It provides real-time data transmission and feedback
to patients on their mobile phone through: (i) trans-
mission of blood glucose test results and real-time
feedback of trends to the mobile phone; (ii) an elec-
tronic patient diary with the facility to record insulin
doses; and (iii) a facility to transmit blood pressure
results and weight. Patients were provided with im-
mediate feedback including summaries and charts of
entered data allowing them to monitor and make
decisions about future self-management (Figure 1).
The telehealth nurse and other clinicians were pro-
vided with access to password protected web-based
summary and feedback screens and the capacity for
automated messaging to patients’ mobile phones for
alerts and reminders. Patient’s telehealth data could be
viewed securely by the telehealth nurse and the patient’s
clinician, without the necessity of a face-to-face visit.
Procedures
The process of using the telehealth system in the study
was designed to match, as far as possible, current
clinical practice for managing insulin treatment for
patients with T2D with the addition of a clinically
feasible protocol for telehealth support. Recruitment
to and participation in the study followed standard
procedures, with patients identiﬁed through review of
practice lists and invitations issued to eligible patients.
Following informed consent, blood samples were
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taken for measurement of HbA1c, lipids and blood
pressure. Patients were oﬀered a standard educational
package with information about the need for insulin
treatment, requirements for blood glucose self-moni-
toring, training with respect to injection technique
and information about what to do in the event of
hypoglycaemia. Clinical staﬀ at each general practice
asked patients to adjust their own insulin dose by two
units every three days based on self-monitored glucose
levels.11 Patients were encouraged to monitor their
blood glucose levels aminimumof once a day according
to the advice of their general practitioner or practice
nurse. Once target blood glucose levels were achieved,
self-monitoring continued less frequently to identify
any further requirement for insulin dose adjustment.
Training in use of the telehealth system was pro-
vided by the telehealth nurse at the ﬁrst study visit.
These visits took place at the patient’s general practice
and the training took between 30 and 60 minutes to
complete. A short training and support manual con-
taining information about use of the system and
viewing data was given to each patient. Following the
initial training session patients were provided with a
mobile telephone number for the telehealth nurse and
were asked to contact her if they had any questions or
problems.
The telehealth nurse reviewed transmitted patient
data every two to three days with the following criteria
formaking additional telephone contactwith the patient
in advance of routine two to four weekly contacts:
. failure to receive blood glucose readings >3 days
. a seven-day trend of higher thanusual blood glucose
readings (fasting blood glucose levels >7.5mmol/l)
. a single record of blood glucose <4mmol/1 or a
diary entry of hypoglycaemia
. patient-speciﬁc excursions from usual trend (see
Box 1 for examples).
Printouts of these readings were also sent to practice
clinical staﬀ every two weeks. The telehealth nurse
encouraged patients to follow the recommendations
Figure 1 Feedback on trends in glucose levels available on the mobile phone
Histogram shows how
many readings taken
and at dif erent levels.
The higher the green
bars, the better the
person is managing
their glucose levels.
Blood glucose results
in a table.
Line chart plotting
readings over time
Scatter chart of last
five days readings
Box 1 Patient case histories illustrating
impact of telehealth intervention
Patient T029 was contacted by his practice nurse
afterﬁvedaysof bloodglucose readings>11mmol/l.
His insulin regimen was reviewed and he was
requested tomake weekly visits until a signiﬁcant
reduction in blood glucose levels was achieved.
At follow-up visits it became clear that he had
beenmissing out insulin doses to facilitate weight
loss. He was referred to a dietitian.
Patient T030 had a blood glucose reading of
30.5 mmol/l and was contacted by the telehealth
nurse who discovered that the patient had drunk
three cans of coca-cola a few hours before per-
forming the test. He was advised about the high
sugar content of ﬁzzy drinks and the association
of sugar and carbohydrate intake and increased
blood glucose levels.
f
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for insulin titration, but clinical care remained with
the practice nurse and general practitioner who were
advised by email or telephone of abnormally high
results or abnormal trends so that they could make
additional recommendations to the patient.
Results
Recruitment
Twenty-three patients were recruited from nine gen-
eral practices across the Thames Valley. Patient char-
acteristics are recorded in Table 1.
Practice views on the technology and
the research
Clinicians reported that they valued three aspects of
the telehealth system: (i) the ability to access up-to-
date information about patients’ blood glucose read-
ings and insulin doses; (ii) the potential to support
patients in making their own adjustments to insulin
regimens; (iii) the opportunity given by the telehealth
system to help patients with diabetes enhance their
personal control over the day-to-day management
of their diabetes. Overall the telehealth system was
perceived by clinical staﬀ to be a valuable support tool
to assist them in implementing and adjusting insulin
regimens for individual patients, particularly during
the ﬁrst few months of conversion and for patients
experiencing ongoing diﬃculties controlling their blood
glucose levels (Box 1).
Six out of the 15 practices approached declined the
opportunity to participate in the study. Reasons given
included: (i) their practice nurses were overstretched
and unable to take on further commitments; (ii) the
general practice was moving premises and would not
take on further work at that time; and (iii) as a policy
decision, the practice did not participate in any
research studies.
During initial meetings between the telehealth nurse
and general practice staﬀ, the following issues were
raised about the use of the mobile phone technology,
most of which required explanation of the concept of
telehealth and healthcare policy:
. the meaning of the term telehealth, both generally
and in relation to the study
. how telehealth relates to the implementation of
national guidelines and policies for information
communications technology
. relevance of telehealth to national and local stan-
dards and guidelines for the support of patients with
diabetes in their day-to-day lives
. current evidence for standards of practice relating to
insulin regimens
. telehealth technology and its appropriateness for
data gathering, data review and interpretation
. conﬁdentiality and anonymity with respect to data
transfer and messaging
. beneﬁts of accessing information via the ‘world
wide web’
. patient data monitoring by a telehealth nurse
. future opportunities and possible developments in
the ﬁeld of telehealth
. scope of interaction between a telehealth nurse and
the practice-based clinicians.
Table 1 Baseline patient characteristics: n=23
% n
Female 20 5
Mean Standard deviation
Age in years 57.6 12.0
Duration of diabetes (months) 77.2 53.6
Weight (Kg) 101.3 26.6
BMI 33.2 6.3
Systolic BP (mmHg) 144 18
Diastolic BP (mmHg) 84 8
HbA1c (%) 9.5 2.2
Insulin dose (units) 51.5 39.5
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None of the nine practice nurses involved in the study
exploited the opportunity to review patients’ trans-
mitted data via web pages. Printouts of data were sent
to practices at two-weekly intervals for information,
but the contact from the telehealth nurse for alerts
where necessary was seen as more valuable.
Patients’ views on the technology
Patients quickly and enthusiastically engaged with the
study and were keen to take part both for their own
beneﬁt and because of the perception that others might
also beneﬁt. They reported feelingmore ‘in control’ of
their diabetes and having increased conﬁdence to self-
manage insulin titration.
During their ﬁrst study visit patients were asked
how frequently theymonitored their bloodglucose levels.
In all cases patients were in the habit of performing a
daily fasting blood glucose reading and in several cases
an additional one or two tests per day following
guidance from their clinician. Individual monitoring
schedules remained as previously speciﬁed and were
not varied due to study participation. All patients had
previously been trained to carry out self-monitoring
of blood glucose although technique in carrying out
the procedure was checked.
Patients were instructed to follow the self-managed
dose adjustment algorithm. The telehealth nurse re-
viewed transmitted glucose results data, either by
computer-prompted or routine two-to-four weekly
telephone follow-ups, and encouraged patients to follow
the self-managed titration schedule. Some patients
reported discontinuing the regimen after a few weeks
because of a concern that they were taking too much
insulin despite daily fasting blood glucose readings
frequently above 7.5mmol/l. Following liaison be-
tween the telehealth nurse and practice-based clinicians,
patients were reassured that they could continue to
follow the titration algorithm with the aim of achiev-
ing an HbA1c <7.5%.
The majority of patients called the telehealth nurse
with questions at least once during the initial two
weeks. Patients who had never used a mobile phone
before required additional support to assist them in
navigating the phone’s menu systems.
Some patients expressed concern that theymight be
‘judged’ on their blood glucose control. Reassurance
was oﬀered, explaining that results would be mon-
itored for trends over time and to ascertain the correct
insulin treatment regimen. Patients were also sur-
prised and reassured to learn that most people had
their ‘bad days’ where their glucose levels were raised
beyond the normal range. This reduced any concerns
patients might have regarding distant monitoring and
motivated them to continue transmitting information
during the course of the study.
Feasibility of the technology
A number of issues relating to use of the technology
were identiﬁed in the early part of the study as a result
of phone calls made by study participants to the
telehealth nurse. These system usage problems were
classiﬁed by call type and actions taken or recommen-
dations given (Table 2).
Interim clinical and technical
outcomes
Mean (SD) HbA1c at baseline was 9.5% (2.2), and the
decrease in HbA1c at three months after the start of
the intervention was 0.52% (0.91) with a mean (SD)
insulin dose increase of nine units (26). A mean (SD)
of 160 (93) blood glucose readings were transmitted
per patient.
Discussion
We found that the concept of telehealth monitoring
was unfamiliar to most patients and practice nurses.
While clinicians valued the additional patient moni-
toring and support that resulted from patients using
the telehealth system, the telehealth nurse carried out
the majority of data review and patient communi-
cation. Patients were enthusiastic about the additional
level of support facilitated by the telehealth system and
felt that the service complemented their primary care
services. Previous experience with a mobile phone
enabled more rapid adoption of the telehealth system.
Early ﬁndings indicate that the transmission of results
is maintained throughout the study.
Clinicians expressed concerns about the extent to
which use of a telehealth approach might lead to
patients becoming increasingly dependent on external
guidance for day-to-day disease management. The
way in which the technology is implemented has
potential to undermine the extent to which patients
are conﬁdent in their own disease self-management.12
One of the principles used in designing the systemwas
that it should not make additional demands on
clinical staﬀ at the practice. Clear agreements would
be needed on the respective roles of the telehealth
nurse and the practice-based clinicians in future im-
plementation of the system. Despite the design of the
system, some concerns about the potential for increased
demands on practice-based clinicians remained, al-
though the beneﬁts of reduced patient travel and ease
of obtaining and reviewing patient data were recog-
nised.
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Following the initial use of technical language to
describe the system, some clinicians expressed con-
cerns that this might mean the requirements of the
study were complex and would require extensive train-
ing. Further discussions using familiar concepts helped
some clinicians engage with the study. Patients could
also ﬁnd the use of jargon oﬀ-putting, while more
technically minded patients requested more detail.
Therefore, training and support documentation need
to address the range of participants’ individual know-
ledge, interests and expertise. People with visual impair-
ment or disturbed touch sensitivity may be unable to
use the current mobile phone technology. However, it
is possible with most mobile phones to increase the
resolution of the screen display. Research would be
required to verify that the larger displays would be
acceptable to people with visual impairment.
Providing support for patients with T2D during the
early stages of insulin treatment is demanding. Future
direction of development of the telehealth system will
depend on the ﬁndings from this and similar studies.
For example, there is the possibility of providing text-
message alerts to the telehealth nurse if patients exper-
ience blood glucose excursions outside a pre-deﬁned
range. Equally, decision support could be directly
targeted at patients and encourage adherence to the
titration regimens. However, there is no current view
on the extent to which advice determined through
an algorithm requires clinician review. New ways of
working are likely to develop that will cut across
traditional boundaries between primary, secondary
and social care.
A telehealth system, such as the one adopted for this
study, provides the means for a telehealth nurse,
liaising with the practice, to better understand a
patient’s insulin usage on a daily basis and to enable
appropriate medication titration. Patients taking part
in this study were able to view their blood glucose
readings in several diﬀerent formats and were aware
that a clinician was also actively monitoring them.
Engaging people with diabetes in their own care is a
core part of the National Service Framework delivery
strategy13 and the high levels of transmission of blood
glucose results and enthusiasm for use of the tech-
nology by patients suggest that it has clinical utility.
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Table 2 Technical problems experienced in using the telehealth system
Call type Action/recommendation
Identiﬁable technical problems, such as phone
transmission or application errors
Normally resolved by the telehealth nurse or escalated
to the application supplier’s front-line support team
Ongoing training relating to certain aspects of the
application or monitoring system
The telehealth nurse provided telephone training or
visited the patient at their home. Additional training
materials were also provided including a step-by-
step user guide and more detailed training manual
Mobile phone service provider problems,
insuﬃcient signal or lack of phone credit
Service provider issues normally due to temporary
network faults and resolved without action. If signal
insuﬃcient patient advised to transmit in area with
stronger signal strength. Phone credit topped up
remotely by telehealth nurse
Bluetooth cradle fault or battery failure Cradle replaced by post or by telehealth nurse visit.
New battery provided
General enquiries, such as ‘I’m going on holiday,
will my phone still work and what do you want
me to do while I’m away?’
Advice and guidance provided by the telehealth
nurse. If patients travelled abroad they were requested
not to use their phones but to continue monitoring
their blood glucose and to download the results on
their return
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